Jemima Stratford QCBarrister at Brick Court Chambers
Jemima Stratford QC is widely recognised as a leading litigator with a broad practice in public law, EU/international, competition and human rights.
Jemima’s EU/international and competition expertise ranges from FRAND licensing to pharmaceuticals, and from free movement to financial services. She is regarded as one of the leading Silks in regulatory matters. Jemima has appeared in more than 50 cases in the General Court and Court of Justice in Luxembourg. Her domestic practice includes competition law cases in the CAT, Commercial Court and Patents Court.
Jemima's public law and human rights work have taken her to the Supreme Court and to the Grand Chamber of the ECtHR. Before taking silk, she was a member of the Attorney General’s ‘A’ Panel. She acts for both claimants and defendants across a wide range of cases, some of which also have a connection with EU law. Jemima also advises both States and international organisations on immunities from jurisdiction, dealing with both public international law and human rights arguments.
Jemima has been called to the Bar of Ireland, and is a member of the Irish Law Library. She has been appointed as a UK panel member for the Withdrawal Agreement Arbitration Panel.
Jemima is widely regarded as a preeminent Silk in pharmaceuticals. She has appeared in very many of the leading cases both domestically and in Luxembourg.
- Novartis v Mylan (Patent Court claim concerning SPC and Paediatric Regulation – Exjade)
- R (Bayer) v 12 CCGs (legality of policy preferring use of unlicensed medicine for treatment of wet AMD) (High Court and CA)
- R (Orion) v MHRA (authorisation of post-operative sedative medicine based on pre-EU accession Czech data)
- R (Teva) v Sec. of State for Health & Biogen (binding nature of recital to Commission Decision and global marketing authorisation concept – Tecfidera)
- Case T-729/15 MSD Animal Health v EMA (access to pharmaceutical documents held by EU - Bravecto)
- Teva v Novartis (Patent Court claim concerning SPC and Paediatric Regulation – Imatinib)
- Accord v Astellas (legality of reliance on German reference product - bendamustine)
- Pfizer (Lyrica/Pregabalin) (public law aspects of second medical use patent)
- Case T-67/13 Novartis v Commission (data exclusivity for cancer drug – Aclasta)
- Case C-477/11 P Sepracor v Commission (admissibility of challenge to decision about new active substance status – eszopiclone)
- Case C-130/11 Neurim Pharmaceuticals (SPC)
- R v Patel & Hussain (CA)  1 WLR 1011 (whether counterfeit viagra placed on the market in the UK)
- Case C-527/07 Generics (ECJ) 18 June 2009 (meaning of 'reference medicinal product' - galantamine)
- Case C-421/07 Damgaard (ECJ) 2 April 2009 (advertising of pharmaceuticals)
- Case C-452/06 Synthon (ECJ) 16 October 2008 (mutual recognition of pharmaceuticals)
- Case C-106/01 R v MCA, ex parte Novartis (High Court, CA and ECJ)  ECR I-4403 (pharmaceutical marketing authorisations)
- Case C-94/98 R v MCA, ex parte RPR (High Court and ECJ)  EuLR 127,  EuLR 181,  ECR I-8789 (parallel imports of pharmaceuticals and test for injunction)
- Case C-368/96 R v MCA, ex parte Generics (ECJ)  ECR I-7967 (pharmaceutical marketing authorisations)